Potential of liposomes for the intravitreal injection of therapeutic molecules;Potentiel des liposomes pour l'injection intravitréenne de molécules thérapeutiques

Annales Pharmaceutiques Francaises

Volumn 69, Issue 2, 2011, Pages 100-107

  Bochot, A ^a   Lajavardi, L ^a   Camelo, S ^b   Bourges, J L ^b   Behar Cohen, F ^b   de Kozak, Y ^b   Fattal, E ^a  

^a UNIV PARIS SUD   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Biodistribution; Intraocular route; Intravitreal injection; Liposomes; Ophthalmology

Indexed keywords

LIPOSOME;

ARTICLE; DRUG DELIVERY SYSTEM; EDEMATOUS MACULOPATHY; ENDOPHTHALMITIS; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LENS DISEASE; RETINA DETACHMENT; RETINA DISEASE; RETINITIS; UVEITIS;

EID: 79953024995     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2010.11.002     Document Type: Article

References (66)

1. Behar-Cohen F. Drug delivery to target the posterior segment of the eye Med. Science 2004, 20:701-706.
2. Heinemann M.H. Long-term intravitreal ganciclovir therapy for cytomegalo-virus retinopathy. Arch Ophthalmol 1989, 107:1767-1772.
3. Jacobson M.A., O'Donnell J.J., Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989, 33:736-741.
4. Bourges J.L., Bloquel C., Thomas A., Froussart F., Bochot A., Azan F., et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliver Rev 2006, 58:1182-1202.
5. Tulli M. L'approche galénique de la corticothérapie appliquée à l'œdème maculaire diabétique [thèse]. Paris-Sud 11: Châtenay-Malabry; 2010. p. 1-90.
6. Bochot A. Administrations topique et intravitréenne de liposomes potentialités et limites en ophtalmologie [thèse]. Dijon: Bourgogne; 2002. p. 1-74.
7. Bochot A., Barbault-Foucher S., Fattal E. Les vecteurs colloïdaux intérêts et limites en ophtalmologie. STP Pharma Prat 2002, 12:42-49.
8. Desmettre T., Mordon S., Soulie S., Devoisselle J.M., Weisslinger J.M. Liposomes in ophthalmology: review of the literature. J Fr Ophtalmol 1996, 19:716-731.
9. Bourlais C.L., Acar L., Zia H., Sado P.A., Needham T., Leverge R. Ophthalmic drug delivery systems - recent advances. Prog Retin Eye Res 1998, 17:33-58.
10. Yasukawa T., Ogura Y., Tabata Y., Kimura H., Wiedemann P., Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 2004, 23:253-281.
11. Kurz D., Ciulla T.A. Novel approaches for retinal drug delivery. Ophthalmol Clin North Am 2002, 15:405-410.
12. Ebrahim S., Peyman G.A., Lee P.J. Applications of liposomes in ophthalmology. Surv Ophthalmol 2005, 50:167-182.
13. Bochot A., Couvreur P., Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res 2000, 19:131-147.
14. Shah S.S., Denham L.V., Elison J.R., Bhattacharjee P.S., Clement C., Huq T., et al. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol 2010, 5:75-93.
15. Korobelnik J.F., Weber M., Cohen S.Y., Experts G. Guidelines for intravitreal injectives (French version). J Fr Ophtalmol 2009, 32:288-289.
16. Henry K., Cantrill H., Fletcher C., Chinnock B.J., Balfour H.H. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987, 103:17-23.
17. Emmanouil M., Lam W. Current trends of intravitreal steroid use in retinal diseases. Can J Ophthalmol 2009, 44:147-153.
18. Zeng S., Hu C., Wei H., Lu Y., Zhang Y., Yang J., et al. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology 1993, 100:1640-1644.
19. Friedrich S., Cheng Y.L., Saville B. Finite element modeling of drug distribution in the vitreous humor of the rabbit eye. Annu Rev Biomed Eng 1997, 25:303-314.
20. Jermak C.M., Dellacroce J.T., Heffez J., Peyman G.A. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007, 52:503-522.
21. Tojo K.J., Ohtori A. Pharmacokinetic model of intravitreal drug injection. Math Biosci 1994, 123:59-75.
22. Coco R.M., Lopez M.I., Pastor J.C., Nozal M.J. Pharmacokinetics of intravitreal vancomycin in normal and infected rabbit eyes. J Ocul Pharmacol Ther 1998, 14:555-563.
23. Peyman G.A., Charles H.C., Liu K.R., Khoobehi B., Niesman M. Intravitreal liposome-encapsulated drugs: a preliminary human report. Int Ophthalmol 1988, 12:175-182.
24. Akula S.K., Ma P.E., Peyman G.A., Rahimy M.H., Hyslop N.E., Janney A., et al. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol 1994, 78:677-680.
25. Bochot A., Fattal E., Boutet V., Deverre J.R., Jeanny J.C., Chacun H., et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 2002, 43:253-259.
26. Lajavardi L. Nouvelle stratégie thérapeutique des uvéites pour l'administration intraoculaire d'un peptide immunomodulateur, le VIP, dans des liposomes [thèse]. Châtnay-Malabry: Université Paris-Sud 11; 2008. p. 1-356.
27. Lajavardi L., Bochot A., Camelo S., Goldenberg B., Naud M.C., Behar-Cohen F., et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci 2007, 48:3230-3238.
28. Bejjani R.A., Jeanny J.C., Bochot A., Behar-Cohen F. The use of liposomes as intravitreal drug delivery system. J Fr Ophtalmol 2003, 26:981-985.
29. Bourges J.L., Touchard E., Kowalczuk L., Berdugo M., Thomas-Doyle A., Bochot A., et al. Drug delivery systems for intraocular applications. J Fr Ophtalmol 2007, 30:1070-1088.
30. Le Bourlais C., Chevanne F., Ropert P., Bretagne G., Acar L., Zia H., et al. Release kinetics of liposome-encapsulated ganciclovir after intravitreal injection in rabbits. J Microencapsul 1996, 13:473-480.
31. Fishman P.H., Peyman G.A., Lesar T. Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Invest Ophthamol Vis Sci 1986, 27:1103-1106.
32. Alghadyan A.A., Peyman G.A., Khoobehi B., Milner S., Liu K.R. Liposome-bound cyclosporine: clearance after intravitreal injection. Int Ophthalmol 1988, 12:109-112.
33. Rao V.S., Peyman G.A., Khoobehi B., Vangipuram S. Evaluation of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis. Int Ophthalmol 1989, 13:181-185.
34. Kim E.K., Kim H.B. Pharmacokinetics of intravitreally injected liposome-encapsulated tobramycin in normal rabbits. Yonsei Med J 1990, 31:308-314.
35. Assil K.K., Hartzer M., Weinreb R.N., Nehorayan M., Ward T., Blumenkranz M. Liposome suppression of proliferative vitreoretinopathy - rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci 1991, 32:2891-2897.
36. Gariano R.F., Assil K.K., Wiley C.A., Munguia D., Weinreb R.N., Freeman W.R. Retinal toxicity of the antimetabolite 5-fluorouridine 5'-monophosphate administered intravitreally using multivesicular liposomes. Retina 1994, 14:75-80.
37. Gupta S., Velpandian T., Dhingra N., Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther 2000, 16:511-518.
38. Zhang R., He R., Qian J.A., Guo J., Xue K., Yuan Y.F. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 2010, 51:3575-3582.
39. Abrishami M., Ganavati S.Z., Soroush D., Rouhbakhsh M., Jaafari M.R., Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 2009, 29:699-703.
40. Barza M., Stuart M., Szoka F. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci 1987, 28:893-900.
41. Onyuksel H., Ikezaki H., Patel M., Gao X.P., Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm Res 1999, 16:155-160.
42. Fattal E., Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliver Rev 2006, 58:1203-1223.
43. Besen G., Flores-Aguilar M., Assil K.K., Kupperman B.D., Gangan P., Pursley M., et al. Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC. Arch Ophthalmol 1995, 113:661-668.
44. Rosenbaum J.T., McDevitt H.O., Guss R.B., Egbert P.R. Endotoxin-induced uveitis in rats as a model for human disease. Nature 1980, 286:611-613.
45. Ruiz-Moreno J.M., Thillaye B., de Kozak Y. Retino-choroidal changes in endotoxin-induced uveitis in the rat. Ophthalmic Res 1992, 24:162-168.
46. Pouvreau I., Zech J.C., Thillaye-Goldenberg B., Naud M.C., Van Rooijen N., de Kozak Y. Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis. J Neuroimmunol 1998, 86:171-181.
47. De Kozak Y., Omri B., Smith J.R., Naud M.C., Thillaye-Goldenberg B., Crisanti P. Protein kinase Czeta (PKCzeta) regulates ocular inflammation and apoptosis in endotoxin-induced uveitis (EIU): signaling molecules involved in EIU resolution by PKCzeta inhibitor and interleukin-13. Am J Pathol 2007, 170:1241-1257.
48. Grajewski R.S., Silver P.B., Agarwal R.K., Su S.B., Chan C.C., Liou G.I., et al. Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med 2006, 203:851-856.
49. Terrada C., Fisson S., De Kozak Y., Kaddouri M., Lehoang P., Klatzmann D., et al. Regulatory T cells control uveoretinitis induced by pathogenic Th1 cells reacting to a specific retinal neoantigen. J Immunol 2006, 176:7171-7179.
50. Camelo S., Lajavardi L., Bochot A., Goldenberg B., Naud M.C., Brunel N., et al. Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. J Ocul Pharmacol Ther 2009, 25:9-21.
51. Camelo S., Lajavardi L., Bochot A., Goldenberg B., Naud M.C., Fattal E., et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol Vis 2007, 13:2263-2274.
52. Camelo S., Lajavardi L., Bochot A., Goldenberg B., Naud M.C., Fattal E., et al. Drainage of fluorescent liposomes from the vitreous to cervical lymph nodes via conjunctival lymphatics. Ophthalmic Res 2008, 40:145-150.
53. Xu J., Heys J.J., Barocas V.H., Randolph T.W. Permeability and diffusion in vitreous humor: implications for drug delivery. Pharm Res 2000, 17:664-669.
54. De Kozak Y., Andrieux K., Villarroya H., Klein C., Thillaye-Goldenberg B., Naud M.C., et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004, 34:3702-3712.
55. Bochot A. Conception et étude d'un système pour l'administration oculaire d'oligonucléotide antisens constitué de liposomes dispersés dans un gel thermosensible [thèse]. Châtenay-Malabry: Université Paris-Sud 11; 1998. p. 1-178.
56. Fattal E., De Rosa G., Bochot A. Gel and solid matrix systems for the controlled delivery of drug carrier-associated nucleic acids. Int J Pharm 2004, 277:25-30.
57. Lajavardi L., Camelo S., Agnely F., Luo W., Goldenberg B., Naud M.C., et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Control Release 2009, 139:22-30.
58. Agnely F., Djedour A., Bochot A., Grossiord J-L. Properties of various thermoassociating polymers: pharmaceutical and cosmetic applications. JDDST 2006, 16:3-10.
59. Bishop P. The biochemical structure of mammalian vitreous. Eye 1996, 10:664-670.
60. Laurent T.C., Fraser J.R. Hyaluronan. J Faseb 1992, 6:2397-2404.
61. Bochot A., Fattal E., Gulik A., Couarraze G., Couvreur P. Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides. Pharm Res 1998, 15:1364-1369.
62. El Sanharawi M., Kowalczuk L., Touchard E., Omri S., de Kozak Y., Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res 2010, 29:443-465.
63. Touchard E., Omri S., Naud M.C., Berdugo M., Deloche C., Abadie C., et al. A peptide inhibitor of c-Jun N-Terminal kinase for the treatment of endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2010, 51:4683-4693.
64. Andrieu-Soler C., Bejjani R.A., de Bizemont T., Normand N., BenEzra D., Behar-Cohen F. Ocular gene therapy: a review of nonviral strategies. Mol Vis Mol Vis 2006, 12:1334-1347.
65. Chappelow A.V., Kaiser P.K. Neovascular age-related macular degeneration: potential therapies. Drugs 2008, 68:1029-1036.
66. Hnik P., Boyer D.S., Grillone L.R., Clement J.G., Henry S.P., Green E.A. Antisense oligonucleotide therapy in diabetic retinopathy. J Diabetes Sci Technol 2009, 3:924-930.